Barinthus Biotherapeutics plc. (BRNS)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch BRNS
See up to 3 months of BRNS. The 7-day demo opens the 1M and 3M ranges and puts BRNS on your watchlist.
Start 7-day demoLatest BRNS insider trades
About Barinthus Biotherapeutics plc. (BRNS)
Barinthus Biotherapeutics plc. is an SEC registrant, filing under CIK 0001828185, classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.
BRNS Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 1 | 361,530 | |
| Derivative transaction | 48 | 4,760,953 | |
| Other acquisition / disposition | 1 | 8,797,770 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
BRNS insider transactions (Form 4)
5110 Form 4 filings on record, the earliest from Jun 10, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oxford Science Enterprises plc | Other | Ordinary Shares | 8,797,770 | $0.11 footnote F2 | $977K | |
| ||||||
| Robin Wright - Director | Derivative | Ordinary Shares | 48,256 footnote F3 | - footnote F3 | - | |
| Robin Wright - Director | Derivative | Share Option (Right to Buy) | 20,394 | $0.00 | - | |
| Robin Wright - Director | Derivative | Share Option (Right to Buy) | 34,328 | $0.00 | - | |
| Robin Wright - Director | Derivative | Share Option (Right to Buy) | 18,604 | $0.00 | - | |
| Robin Wright - Director | Derivative | Share Option (Right to Buy) | 19,197 | $0.00 | - | |
| Robin Wright - Director | Derivative | Share Option (Right to Buy) | 19,516 | $0.00 | - | |
| Robin Wright - Director | Derivative | Share Option (Right to Buy) | 20,174 | $0.00 | - | |
| ||||||
| Joseph Scheeren - Director | Derivative | Ordinary Shares | 23,000 footnote F3 | - footnote F3 | - | |
| Joseph Scheeren - Director | Derivative | Share Option (Right to Buy) | 34,328 | $0.00 | - | |
| Joseph Scheeren - Director | Derivative | Share Option (Right to Buy) | 18,604 | $0.00 | - | |
| Joseph Scheeren - Director | Derivative | Share Option (Right to Buy) | 19,197 | $0.00 | - | |
| Joseph Scheeren - Director | Derivative | Share Option (Right to Buy) | 19,516 | $0.00 | - | |
| Joseph Scheeren - Director | Derivative | Share Option (Right to Buy) | 20,174 | $0.00 | - | |
| ||||||
| Anne M. Phillips - Director | Derivative | Ordinary Shares | 3,000 footnote F3 | - footnote F3 | - | |
| Anne M. Phillips - Director | Derivative | Share Option (Right to Buy) | 34,328 | $0.00 | - | |
| Anne M. Phillips - Director | Derivative | Share Option (Right to Buy) | 18,604 | $0.00 | - | |
| Anne M. Phillips - Director | Derivative | Share Option (Right to Buy) | 19,197 | $0.00 | - | |
| Anne M. Phillips - Director | Derivative | Share Option (Right to Buy) | 19,516 | $0.00 | - | |
| Anne M. Phillips - Director | Derivative | Share Option (Right to Buy) | 20,174 | $0.00 | - | |
| ||||||
| Pierre A. Morgon - Director | Derivative | Ordinary Shares | 10,506 footnote F3 | - footnote F3 | - | |
| Pierre A. Morgon - Director | Derivative | Share Option (Right to Buy) | 20,394 | $0.00 | - | |
| Pierre A. Morgon - Director | Derivative | Share Option (Right to Buy) | 34,328 | $0.00 | - | |
| Pierre A. Morgon - Director | Derivative | Share Option (Right to Buy) | 18,604 | $0.00 | - | |
| Pierre A. Morgon - Director | Derivative | Share Option (Right to Buy) | 19,197 | $0.00 | - | |
| Pierre A. Morgon - Director | Derivative | Share Option (Right to Buy) | 19,516 | $0.00 | - | |
| Pierre A. Morgon - Director | Derivative | Share Option (Right to Buy) | 20,174 | $0.00 | - | |
| ||||||
| Leon Hooftman - Officer | Grant or award | Ordinary Shares | 361,530 footnote F3 | - footnote F3 | - | |
| Leon Hooftman - Officer | Derivative | Ordinary Shares | 361,530 footnote F3 | - footnote F3 | - | |
| Leon Hooftman - Officer | Derivative | Share Option (Right to Buy) | 195,166 | $0.00 | - | |
| Leon Hooftman - Officer | Derivative | Share Option (Right to Buy) | 140,000 | $0.00 | - | |
| ||||||
| Alex Hammacher - Director | Derivative | Ordinary Shares | 3,000 footnote F3 | - footnote F3 | - | |
| Alex Hammacher - Director | Derivative | Share Option (Right to Buy) | 34,328 | $0.00 | - | |
| Alex Hammacher - Director | Derivative | Share Option (Right to Buy) | 18,604 | $0.00 | - | |
| Alex Hammacher - Director | Derivative | Share Option (Right to Buy) | 19,197 | $0.00 | - | |
| Alex Hammacher - Director | Derivative | Share Option (Right to Buy) | 19,516 | $0.00 | - | |
| Alex Hammacher - Director | Derivative | Share Option (Right to Buy) | 20,174 | $0.00 | - | |
| ||||||
| William Enright - Officer | Derivative | Ordinary Shares | 728,454 footnote F3 | - footnote F3 | - | |
| William Enright - Officer | Derivative | Ordinary Shares | 514,923 footnote F3 | - footnote F3 | - | |
| William Enright - Officer | Derivative | Share Option (Right to Buy) | 176,130 | $0.00 | - | |
| William Enright - Officer | Derivative | Share Option (Right to Buy) | 359,605 | $0.00 | - | |
| William Enright - Officer | Derivative | Share Option (Right to Buy) | 440,000 | $0.00 | - | |
| William Enright - Officer | Derivative | Share Option (Right to Buy) | 443,981 | $0.00 | - | |
| William Enright - Officer | Derivative | Share Option (Right to Buy) | 600,000 | $0.00 | - | |
| ||||||
| Karen A. Dawes - Director | Derivative | Ordinary Shares | 1,700 footnote F3 | - footnote F3 | - | |
| Karen A. Dawes - Director | Derivative | Share Option (Right to Buy) | 34,328 | $0.00 | - | |
| Karen A. Dawes - Director | Derivative | Share Option (Right to Buy) | 18,604 | $0.00 | - | |
| Karen A. Dawes - Director | Derivative | Share Option (Right to Buy) | 19,197 | $0.00 | - | |
| Karen A. Dawes - Director | Derivative | Share Option (Right to Buy) | 19,516 | $0.00 | - | |
| Karen A. Dawes - Director | Derivative | Share Option (Right to Buy) | 20,174 | $0.00 | - | |
| ||||||
| Karen A. Dawes - Director | Grant or award | Share Option (Right to Buy) | 20,174 | $0.00 | - | |
Item 1.02, 2.01, 3.01, 3.03, 5.01, 9.01
Item 3.01, 8.01
Item 3.01, 7.01, 8.01, 9.01
Item 2.02, 9.01
BRNS insider trading FAQ
What is the latest insider trade for BRNS?
Barinthus Biotherapeutics plc. (BRNS) had 9 insider filings in the last 90 days, with the most recent on 2026-09-11. The full record for BRNS runs to 10 Form 4 filings, the earliest from 2025-06-10. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying BRNS stock?
No insider purchases of BRNS were filed in the last 90 days.
How many insiders are selling BRNS stock?
No insider sales of BRNS were filed in the last 90 days.
Where can I see BRNS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects BRNS Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Oxford Science Enterprises plc view on EDGAR
- - Robin Wright view on EDGAR
- - Joseph Scheeren view on EDGAR
- - Anne M. Phillips view on EDGAR
- - Pierre A. Morgon view on EDGAR
- - Leon Hooftman view on EDGAR
- - Alex Hammacher view on EDGAR
- - William Enright view on EDGAR
- - Karen A. Dawes view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where BRNS's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow BRNS with a 7-day demo
- BRNS on your watchlist
- Every BRNS Form 4 filing on record
- Up to 3 months of BRNS price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
